Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.
GeneDx Holdings Corp. (Nasdaq: WGS), commonly referred to as GeneDx, regularly issues news focused on rare disease genomics, clinical impact, and corporate developments. The company describes itself as the global leader in rare disease diagnosis and a pioneer in genomic medicine, emphasizing the role of exome and genome sequencing and its GeneDx Infinity dataset in transforming care.
News updates from GeneDx often highlight financial results and guidance, including revenue trends, exome and genome test volumes, and margin profiles, alongside commentary on how these metrics relate to the company’s growth in genomic testing. Earnings releases may be accompanied by details on conference calls and investor presentations.
GeneDx also publishes frequent announcements on scientific and clinical milestones. These include peer‑reviewed publications, participation in large genomic newborn screening programs such as GUARDIAN and BEACONS, and recognition of its research by major medical journals. The company’s news flow covers conference presentations, advances in rapid genome sequencing, and developments in long‑read sequencing and gene–disease discovery.
Additional news items describe new test offerings like GenomeDx Prenatal, leadership appointments in medical and business roles, and partnerships such as the collaboration with Komodo Health to link GeneDx Infinity with real‑world healthcare data. For readers following WGS, this news page provides a centralized view of GeneDx’s financial disclosures, research output, clinical initiatives, and strategic collaborations in rare disease genomics.
GeneDx (Nasdaq: WGS) announced the publication of the Seqfirst-neo study results in the American Journal of Human Genetics, conducted with Seattle Children's and the University of Washington. The study introduces a new approach using exclusion criteria for rapid genome sequencing (rGS) in NICU settings, demonstrating that at least 60% of level IV NICU infants should receive rGS.
Key findings from the 408-infant study showed that 49.2% of infants in the interventional group received a precise genetic diagnosis (PrGD), compared to 9.7% in conventional care. The study revealed that 42% of diagnosed infants would have been missed using conventional protocols, with 69% being non-white. The new approach led to clinical management changes in nearly 97% of diagnosed cases.
GeneDx also announced the launch of ultraRapid Whole Genome Sequencing, offering results in as soon as 48 hours for NICU and PICU patients, and integration with Epic Aura to streamline genetic diagnoses delivery.
GeneDx (WGS) has announced the launch of ultraRapid Whole Genome Sequencing, delivering genomic insights for NICU and PICU patients in as fast as 48 hours. This accelerated testing addresses the critical underutilization of genetic testing in NICUs, where up to 25% of patients likely have genetic disorders, yet less than 5% undergo testing.
The service, available for ordering in March through the GeneDx portal and Epic Aura integration, can lead to healthcare savings exceeding $15,000 per child by reducing unnecessary treatments and shortening NICU stays. Without genetic diagnosis, NICU stays are typically 15-20 days longer. The company's advanced technology and experience in sequencing over 750,000 exomes and genomes enables efficient testing at scale.
Genetic diseases are the leading identifiable cause of infant death, and genetic diagnosis can impact clinical management for more than 60% of critically ill infants.
GeneDx (Nasdaq: WGS), a leader in genomic insights and health outcomes, has announced its participation in the 45th Annual TD Cowen Health Care Conference in Boston, MA, from March 3-5, 2025. The company's management will engage in a fireside chat on March 4, 2025, at 1:10 p.m. ET.
The presentation will be accessible through a live and archived webcast on the company's investor relations website. GeneDx specializes in translating complex genomic data into clinical solutions through their industry-leading exome and genome tests, supported by one of the world's largest rare disease data sets. Their mission focuses on delivering personalized medical care through genetic diagnosis, contributing to drug discovery advancement and healthcare system optimization.
GeneDx (WGS) announced its integration with Epic's specialty diagnostics suite, Aura, enabling health systems to order and receive genetic sequencing results directly within their electronic health records (EHR). UNC Health becomes the first health system to implement this integration, with additional health systems now able to access GeneDx's testing services including exome sequencing, whole genome sequencing, and rapid whole genome sequencing.
The integration streamlines the genetic testing process, making results more accessible and visible within patient records. GeneDx has significant experience in genetic testing, having sequenced over 750,000 exomes and genomes, and maintains one of the largest rare disease data sets. The company's services are trusted by 8 out of 10 genetics experts for exome and genome testing.
GeneDx (WGS) has announced it will release its fourth quarter and full year 2024 financial results before market opening on Tuesday, February 18, 2025. The company will host a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results.
Investors interested in participating must register online, and a live and archived webcast will be available on the company's investor relations website. GeneDx specializes in genomic diagnostics, leveraging one of the world's largest rare disease data sets to provide exome and genome testing services that aim to improve personalized healthcare and drug discovery.
GeneDx Holdings Corp. (Nasdaq: WGS) has announced the granting of 69,089 restricted stock units (RSUs) to three newly-hired employees, effective January 14, 2025. Of these, 37,497 RSUs were granted to Bryan Dechairo as part of his employment package as Chief Operating Officer. The RSUs were awarded under GeneDx's 2023 Equity Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). The grants will vest in equal annual installments over four years, contingent on continued employment. Each RSU represents the right to receive one share of GeneDx's Class A Common Stock upon settlement.
GeneDx Holdings Corp. (WGS) has announced strong preliminary financial results for Q4 and full year 2024, exceeding previous guidance. The company expects full-year 2024 revenues of at least $299 million, representing a 54% year-over-year increase, and Q4 2024 revenues of at least $92 million, up 59% year-over-year and 20% sequentially.
The company's exome and genome test revenues reached at least $75.8 million in Q4 2024, showing a remarkable 93% year-over-year increase. Adjusted gross margin is expected to be at least 64% for full year 2024 and 68% for Q4. The results include a $6.8 million discrete benefit from a multi-year appeal recovery. Exome and genome test volume grew to 20,676 in Q4, representing a 32% year-over-year increase and comprising 38% of all test result volume.
GeneDx (WGS) has announced a new telehealth pathway to expand access to genetic testing services, specifically focusing on exome testing for families seeking diagnoses. The initiative aims to reduce the current 4-5 year average diagnostic timeline for rare diseases by connecting parents directly with genetic experts.
The company highlights that children with neurodevelopmental disorders typically incur over $10,000 in additional health costs and undergo more than 5 uninformative tests during their diagnostic journey. Through this new telehealth service, parents can schedule testing, appointments, and potentially receive a diagnosis in as soon as five weeks by visiting GeneDx.com/get-exome.
The company is partnering with a leading telehealth genetics provider to streamline the referral process. This initiative addresses increasing wait times for medical genetics and developmental/behavioral pediatricians, which have grown significantly over the past three years.
GeneDx (Nasdaq: WGS) has demonstrated significant leadership in genomics research throughout 2024, contributing to over 85 peer-reviewed publications and impacting the results of more than 22,000 patients through gene-disease relationship studies. The company has become the largest contributor to GeneMatcher, accounting for 22.2% of all submissions with over 21,315 entries.
The research efforts have led to 26 publications expanding knowledge of known disease-gene associations and 35 publications reporting new disease-gene relationships. Nearly 150 GeneDx ordering clinicians were included as co-authors in 2024, bringing the total to 638 unique ordering clinician co-authors. These contributions have influenced the broadening of phenotypes, discovery of new disease mechanisms, and new modes of inheritance, affecting 12% of all patients receiving exome or genome sequencing from GeneDx.
GeneDx (Nasdaq: WGS) has appointed Bryan Dechairo as Chief Operating Officer, effective immediately. In this newly created role, Dechairo will report to CEO Katherine Stueland and oversee Product & Technology, Operations, Medical Affairs, Innovation, and Program Management teams.
Dechairo brings over 30 years of experience in diagnostic businesses and most recently served as President and CEO of Sherlock Biosciences. He holds a PhD in Human Genetics from University College London and has held executive roles at companies including Pfizer, Myriad Genetics, Assurex, and Medco Health.
The appointment aims to drive operational excellence as GeneDx enters its next phase of commercial growth. The company specializes in pediatric genetics and focuses on delivering personalized health insights for diagnosis, treatment direction, and drug discovery through genomic testing and interpretation services.
FAQ
What is the current stock price of GeneDx Holdings (WGS)?
What is the market cap of GeneDx Holdings (WGS)?
